ReviewCurrent opinion in HIV and AIDS2011
Cardiovascular disease in HIV infection.
Review in Current opinion in HIV and AIDS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Pooled it
- HIV, Vascular Risk Factors, and Cognition in the Combination Antiretroviral Therapy Era: A Systematic Review and Meta-Analysis.Journal of the International Neuropsychological Society : JINS · 2021Pooled it
- Interventions for tobacco use cessation in people living with HIV and AIDS.The Cochrane database of systematic reviews · 2016Pooled it
- Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.Drugs in R&D · 2018Trial
- Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy.Scientific reports · 2016Trial
- Mediators of a smoking cessation intervention for persons living with HIV/AIDS.Drug and alcohol dependence · 2015Trial
- Characterization of platelet-monocyte complexes in HIV-1-infected individuals: possible role in HIV-associated neuroinflammation.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Prevalence and associated factors of malnutrition among adults living with HIV on ART: a pilot study.Metabolism open · 2026Article
- Identification of Clinical Phenotypes Among People with HIV Using Electronic Health Record Data.AIDS and behavior · 2026Article
- A qualitative investigation of tobacco use and cessation experiences among people living with HIV in Botswana.Discover public health · 2026Article
- Burden of heat stress on residual work capacity among farmers living with chronic HIV in Siaya county, Kenya: a longitudinal observational study protocol.BMC public health · 2025Observational
- Wearable device monitoring of HIV health in the face of climate change and weather exposures: protocol for a mixed-methods study.BMJ open · 2025Article
- Influence of antiretroviral therapy on frailty among people living with HIV.Scientific reports · 2025Observational
- Health Data Sciences and Cardiovascular Disease in Africa: Needs and the Way Forward.Current atherosclerosis reports · 2024Review
- Design and rationale of the Botswana Smoking Abstinence Reinforcement Trial: a protocol for a stepped-wedge cluster randomized trial.Implementation science communications · 2024Article
- Hypertension and traditional risk factors for cardiovascular diseases among treatment naïve HIV- infected adults initiating antiretroviral therapy in Urban Tanzania.BMC cardiovascular disorders · 2023Article
- So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.Viruses · 2022Review
- The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.Frontiers in immunology · 2022Review
- Article
- Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA.Journal of applied biomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewHighly active antiretroviral therapy (HAART) use has markedly reduced AIDS-related mortality and opportunistic illness. With improved survival, cardiovascular disease (CVD) has emerged as an important noninfectious chronic comorbidity among antiretroviral (ARV)-treated HIV-infected persons. RECENT
findingsHIV infection can impact CVD and comorbidities known to increase CVD risk. Untreated HIV can cause proatherogenic elevations in serum lipids. Chronic HIV viremia results in increases in systemic inflammation, hypercoagulation, and reductions in endovascular reactivity, all of which are at least partially reversible with virally suppressive HAART. Chronic T-cell activation can also result in adverse vascular effects. Use of some ARV drugs can impact CVD risk by causing pro-atherogenic serum lipid elevations, induction of insulin resistance, increases in visceral adiposity or subcutaneous fat loss. Abacavir use may increase myocardial infarction risk by reducing vascular reactivity and/or increasing platelet activation. Traditional risk factors such as advancing age, smoking, hyperlipidemia, and hypertension remain important predictors of CVD among HAART-treated HIV-infected persons. SUMMARY: HIV in the HAART era is a chronic manageable condition. CVD is an important cause of morbidity among HIV-infected persons. Untreated HIV can increase CVD risk in several ways and these effects are at least partially reversible with successful treatment. Use of specific ARVs can adversely impact CVD risk but the multiple long-term benefits of chronic HIV suppression and immune reconstitution achievable with potent HAART outweigh the adverse impact upon CVD risks that they may have. Standard CVD screening and risk-reducing interventions should be routinely undertaken for HIV-infected persons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.